Alzheimers Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Eisai, Biogen, vTv Therapeutics, AZTherapies, Cerecin, EIP Pharma, Neuraly, AB Science and Others

Alzheimers Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Eisai, Biogen, vTv Therapeutics, AZTherapies, Cerecin, EIP Pharma, Neuraly, AB Science and Others

“Alzheimers Disease Pipeline”

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. In most people with the disease—those with the late-onset type—symptoms first appear in their mid-60s. Early-onset Alzheimer’s occurs between a person’s 30s and mid-60s and is very rare. Alzheimer’s disease is the most common cause of dementia among older adults.

DelveInsight’s, “Alzheimer’s Disease Pipeline Insights, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 


Get free sample report:


Some of Alzheimer’s Disease Companies:

  • Eisai
  • Biogen
  • Changchun Huayang High-tech Co. Ltd.
  • Hoffmann-La Roche
  • vTv Therapeutics
  • AZTherapies
  • Cerecin
  • Neurotrope
  • Lyndra
  • AC Immune
  • INmune Bio
  • Cassava Sciences
  • EIP Pharma
  • Neuraly
  • AB Science
  • Cortexyme
  • Anavex Life Sciences
  • Athira Pharma
  • Time Therapeutics
  • Prilenia Therapeutics
  • Denali Therapeutics Inc.
  • And Many Others


Get free sample report:


Alzheimers Disease Symptoms

Alzheimer’s disease is a progressive condition therefore the symptoms get worse over time. Memory loss is a key feature, and this tends to be one of the first symptoms to develop.

Other symptoms are:

  • Cognitive deficits.
  • Problems with recognition
  • Problems with spatial awareness
  • Problems with speaking, reading, or writing

Later symptoms include impaired communication, disorientation, confusion, poor judgment, behavioral changes and, ultimately, difficulty speaking, swallowing and walking.

As the disease progresses, neurons in other parts of the brain are damaged or destroyed.


Some of Alzheimers Disease Therapies:

  • BAN2401
  • Elenbecestat (E2609)
  • Octohydroaminoacridine Succinate
  • Gantenerumab
  • Azeliragon (TTP488)
  • ALZT-OP1
  • AZT-211
  • Tricaprilin
  • Bryostatin-1
  • Donepezil/memantine extended release
  • ACI-3024
  • INB03
  • Sumifilam
  • Neflamapimod
  • Pegylated exenatide
  • Masitinib
  • Atuzaginstat
  • Blarcamesine
  • NDX-1017
  • Bromocriptine
  • Pridopidine
  • DNL788


Get free sample report:


Table of Contents:


Executive Summary

Alzheimer’s Disease (AD): Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Alzheimer’s Disease (AD) – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Alzheimer’s Disease (AD) Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

BAN2401: Eisai

Mid Stage Products (Phase II)

• Comparative Analysis

Bryostatin-1: Neurotrope

Early Stage Products (Phase I)

• Comparative Analysis

INB03 – INmune Bio

Pre-clinical and Discovery Stage Products

• Comparative Analysis

AZT-211: AZTherapies

Inactive Products

• Comparative Analysis

Alzheimer’s Disease (AD) Key Companies

Alzheimer’s Disease (AD) Key Products

Alzheimer’s Disease (AD)- Unmet Needs

Alzheimer’s Disease (AD)- Market Drivers and Barriers

Alzheimer’s Disease (AD)- Future Perspectives and Conclusion

Alzheimer’s Disease (AD) Analyst Views

Alzheimer’s Disease (AD) Key Companies


Request for Detailed TOC:


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States